# **1** Title:

Cost of hypertension illness and associated factors among patients
attending hospitals in Southwest Shewa Zone, Oromia Regional State,
Ethiopia.

# 5 Authors:

6 Addisu Bogale<sup>1</sup>, Teferi Daba<sup>2</sup>, Dawit Wolde Daka<sup>2</sup>

- 8 <sup>1</sup> Southwest Shewa zone health office, Woliso, Southwest Ethiopia.
- 9 <sup>2</sup> Faculty of Public Health; Department of Health Economics, Management and Policy; Jimma
- 10 University, Jimma, Ethiopia.
- 11 Co-author contact details:
- 12 Addisu Bogale, E-mail: addisuub@gmail.com ; Teferi Daba, E-mail: tefedha@gmail.com
- 13 Corresponding author:
- 14 Full name: Dawit Wolde Daka
- 15 P.O.Box=378, Jimma University, Jimma, Ethiopia.
- 16 Tel. (+251)-966763913
- 17 E-mail: <u>dave86520@gmail.com</u>

## 18 Abstract

**Background:** Hypertension is a common vascular disease and the main risk factor for cardiovascular diseases. The impact of hypertension is on the rise in Ethiopia, so that, it is predictable that the cost of healthcare services will further increase in the future. We aimed to estimate the total cost of hypertension illness among patients attending hospitals in Southwest Shewa zone, Oromia Regional State, Ethiopia.

Patients and methods: Institution based cross-sectional study was conducted from July 1-30, 2018. All hypertensive patients who were on treatment and whose age was greater than eighteen years old were eligible for this study. The total cost of hypertension illness was estimated by summing up the direct and indirect costs. Bivariate and multivariate linear regression analysis was conducted to identify factors associated with hypertension costs of illness.

**Results:** Overall, the mean monthly total cost of hypertension illness was US \$ 22.3 (95% CI, 21.3-23.3). Direct and indirect costs share 51% and 49% of the total cost, respectively. The mean total direct cost of hypertension illness per patient per month was US \$11.39(95% CI, 10.6-12.1). Out of these, drugs accounted of a higher cost (31%) followed by food (25%). The mean total indirect cost per patient per month was US \$10.89(95% CI, 10.4-11.4). Educational status, distance from hospital, the presence of companion and the stage of hypertension were predictors of the cost of illness of hypertension.

36 Conclusion: The cost of hypertension illness was very high when compared with the mean 37 monthly income of the patients letting patients to catastrophic costs. Therefore, due attention 38 should be given by the government to protect patients from financial hardships.

39 Key words: Illness, total cost, direct cost, indirect cost, Region, Ethiopia.

## 40 Introduction

Hypertension is one of the main public health problem seen among adults worldwide.
Hypertension is often defined as Systolic Blood Pressure (SBP) ≥140 mmHg or Diastolic Blood
Pressure (DBP) ≥90 mmHg. It is the main risk factor to cardiovascular disease (CVD) such as
heart diseases and stroke (1,2).

Worldwide, 45% of deaths as the result of heart diseases and 51% of deaths due to stroke was attributable to hypertension(3). In 2012 alone, 17.5 million people were died due to CVDs, which translated to every three people deaths in ten (4). Out of these deaths, over half, 9.4 million, deaths are caused by complications of hypertension(4,5). Hypertension was the fourth and seventh contributor to premature deaths in developed and developing countries , respectively (6).

50 The prevalence of hypertension is in a high rise wordwide over time (7) and the prevalence varies across the different regions and country income groups. Recent evidences indicated that an 51 estimated 1.13 billion people have hypertension worldwide. Out of these, the majority (around two 52 thirds) were located in low and middle income countries. The prevalence ranged from 27% in the 53 54 World Health Organization (WHO) Africa region to 18% in the WHO region of Americans. The high rise in the prevalence of hypertension was attributed to the increase in the risk factors such as 55 physical inactivity, the consumption of tobacco and alcohol, unhealthy diet, overweight and obesity 56 in those population groups (2,7). 57

In Ethiopia evidences showed that the prevalence and impact of non-communicable diseases (NCDs) including hypertension has increased over time(8). A meta analysis and other surveys conducted in different parts of Ethiopia revealed that the prevalence of hypertesion was increasing in Ethiopia. The prevalence was high and ranged from 24.4% to 34.7% (9–13). The latest WHO

published data in 2017 indicated that deaths attributed to hypertension reached 11,050 deaths or 1.74% of the total deaths in Ethiopia. The age adjusted death rate in Ethiopia was 25.14 per 100,000 of population and this ranked Ethiopia 38<sup>th</sup> in the world. Hypertension was ranked 11<sup>th</sup> out of the top 20 causes of death in the country(14). Ethiopia was prone to double burden of diseases, both infectious and non-infectious diseses, that requires a urgent government actions(15).

The government of Ethiopia (GoE) has expressed its commitment for tacking premature deaths attributed to non-communicable diseases by signing the sustainable development goals (SDGs)(16) and incorporating related targets within the national health sector transformation plan (HSTP)(17). To effect this target, a comprehensive prevention and control strategic action plan of NCDs including hypertension was developed at national level with a particular emphasis to reducing risky behaviors(18).

73 Cost of health services is important determinant of the acceptability and utilization of health services by the society. The goal of health system is improving the health conditions of citizens 74 75 through protecting financial catastrophes or hardships(19,20). The management of hypertension is cost intensive and hence, it may cause economic burden on citizens(21-24). Society may not afford 76 available services leading to ineffectiveness of hypertension managements (25). Hypertension cost 77 of illness was determined by various factors such as the presence of co-morbidity, stage of illness 78 79 and distance to health facility (22,26). Therefore, it is crucial to quantify the cost of hypertension 80 illness and identify the factors that determines the cost of hypertension illness among patients in Ethiopia. 81

Available investigations on the cost of hypertension illness in Ethiopia have focused on the direct costs of illness (26) and to our best knowledge little was known about the indirect costs of hypertension illness. Hence, the aim of this study was to estimate the cost of hypertension illness

among patients in four hospitals of Southwest Shewa zone, Oromia Regional State, Ethiopia. We
estimated the direct, indirect and total costs of hypertension illness. Moreover, we tried to identify
the potential predictors of the total costs of hypertension illness.

## 88 **Patients and methods**

### 89 Study setting

The study was conducted in four hospitals of Southwest Shewa zone from August 13 to September 2, 2018. Southwest Shewa zone is one among the zonal administrations located in Oromia Regional State, 114 km far away from the capital city of Ethiopia, Addis Ababa. The total population of the zone was 1,101,129. Southwest Shewa zone comprised of 3 government hospitals, 1 other government organization (OGO) hospital, 54 health centers and 264 health posts. The hospitals were named as St. Luke general hospital; Tulo Bolo, Ameya and Bantu primary hospitals, respectively.

97 These hospitals provides high level curative services such as the management of non-98 communicable diseases like hypertension, diabetes, coronary heart diseases and stroke to the 99 catchment population of the zone and neighboring zones.

### 100 Study design and participants

Institution based cross-sectional study design was employed and the perspective of patients was used to estimate the cost of hypertension illness. All hypertensive patients who were on followup at hospitals and whose age was greater than 18 years old and who have been taken antihypertensive medications were eligible for this study. Pregnant women were excluded from this study to avoid gestational hypertension, as its effect may not last long.

106 Study sample size was determined using a single population mean formula(27). A previous report 107 from Ethiopia public hospitals indicated that the mean or median drug prescription cost of 108 hypertension was 100 Ethiopian Birr (ETB) or US \$ 3.6 (SD 41.19 or 1.5)(26). By using the 109 assumptions above, the estimated sample size at 95% confidence interval and 4% absolute 110 allowable error (precision) yields 408 patients.

111 Sample size (n) = 
$$\frac{(Z_{1-\alpha/2})^2 . (SD)^2}{(d)^2}$$

112 Where;

- 113  $\checkmark$  Z1- $\alpha/2$ =is the value obtained from the standard normal distribution table for 100 (1- $\alpha$ ) % 114 confidence level and its value for 95% confidence level was 1.96.
- 115  $\checkmark$  SD= is the population standard deviation (41.19)(26)
- 116  $\checkmark$  d=is the absolute allowable error (or precision) in the estimation (4% of 100birr =4birr).
- 117 The allowable error in estimating the average cost of prescription of drug for hypertension118 was 4 birr.
- Though, as the number of hypertension patients on follow-up care (source population)) were less than 10,000 in the study area (N=1451), we corrected the sample size to the actual population size and this yields 318 patients. While, by adding 10% of non-response rate, the final estimated sample size yields 354 patients.

Sample size correction formula (nf) = 
$$\frac{n0}{1 + \frac{n0}{N}}$$

124 The calculated sample size was proportionally allocated to each of the study hospitals based on 125 the caseload or hypertension patients per month. Accordingly, the number of patients per month

and sample size allocated for each hospitals were: St. Luke General hospital (N=620, n=152); Tulu
Bolo hospital (N=315, n=76); Amaya hospital (N=241, n=59); and Bantu hospital (N=275, n=67).
Each eligible patients who were presented to the study hospitals during the data collection period
were approached and interviewed.

#### 130 Measurement

A structured data collection tools were used to gather data. The contents of the questionnaires were
developed based WHO protocol for survey to determine costs of TB treatment program (28)and
other related literatures(26).

The contents of the questionnaires were translated to local language (Afan Oromo) by an 134 experienced translator and back translated to English with an independent translator for 135 consistency. Five data collectors with a qualification of diploma nurse and who had also received 136 additional training on the data collection questionnaires and research ethics were participated on 137 data collection. The overall data collection processes were closely monitored and supervised by 138 two health professionals who had a qualification of bachelor's degree. Each eligible patients who 139 140 visits the hospitals were approached and interviewed after explaining the aim of the study and obtaining a consent for participation. 141

### 142 Techniques of cost estimation

The cost of hypertension illnesses analysis was conducted from the perspective of patients and a prevalence based model was employed to estimate cost(29). The main outcome variable was total cost of hypertension illness and it referred to the cost paid by patients as a consequence of a hypertension illness, typically it included both the direct and the indirect costs associated with

hypertension illness. That means, total cost equals to the sum of direct and indirect cost ofhypertension illness.

Direct cost referred to the opportunity cost of resources used for treating hypertension patients such as direct medical cost and direct non-medical cost. Direct medical cost was the amount of money that was paid for registration, laboratory investigation and medication or drugs in the study health facilities during the data collection period as presented below:

153 Cost of hospital admission=Number of days admitted multiplied by cost per day

154 > Investigation cost=Number of investigations carried out multiplied by cost of each
 155 investigations (unit price)

156  $\triangleright$  Cost of drug=Number of prescription given multiplied by cost of each drugs (unit price)

Direct non-medical costs referred to the amount of money that was paid for transportation, food, and accommodation for both patients and their caregiver (companion) to visit the hospital. Transportation costs were estimated based on the number of visits made to hospitals (round trips) to seek care and logging or accommodation costs were estimated based on the number of days of stay at hospitals as described below:

- 162 > Cost of transportation=Number of round trips from home to care provider multiplied by
  163 the cost of single trip
- 164 Cost of lodging or accommodation=Money spent for food and accommodations multiplied
   165 by number of days patients and their companion were away from their home

Indirect cost was the value of resources lost due to a particular illness. Indirect costs were associated with loss of working time of the hypertension patients and their caregivers (companion). The loss of income of a person was due to absenteeism or missing a business appointment. Loss of income or earning was calculated for both employed and unemployed patients as shown below:

170 
$$\blacktriangleright$$
 Loss of earning for employed =  $\frac{Previous monthly income * length of stay}{No of day in the month}$ 

171  $\blacktriangleright$  Loss of earning for unemployed =  $\frac{Previous \ daily \ wage \ rate(minimum \ wage)*length \ of \ stay}{No \ of \ working \ day \ in \ the \ month}$ 

172 The costs of illnesses (both direct and indirect) were estimated as expressed for a 30-day period.

173 The valuation of direct and indirect costs were based on a record review and patients recall.

The direct costs of hypertension illness were estimated by using micro-costing and bottom-up approaches(29). Accordingly, the healthcare consumptions were collected at individual patient level and the illness costs were also modeled at the same level. The direct costs such as costs of drugs, laboratory investigations and registrations were estimated based on the amount consumed by each patients. Health care consumption data were obtained through review of hospitals outpatient department (OPD) registration books and follow-up cards.

The indirect costs were estimated in terms of the productivity time losses of patients and their caregivers (companion). The human capital approach was used to value the productity time losses(29). Indirect costs were estimated for patients' time lost from work during travel and consultation at care providers. First, the time forgone in seeking care and the productivity time lost were estimated. Then, the time forgone in seeking care and the productivity time lost were converted in to the daily indirect costs based on the daily wage rate. Finally, the value obtained by doing so was multiplied by the number of working days lost.

For monthly paid patients and companion, the daily wage rate was estimated by dividing their net monthly salary by 30 days. The income loses to patients who had no permanent job and farmers were estimated using local daily wage rate (Ethiopian birr per day) for unskilled labor and number of working days per month. The local daily wage rate for unskilled labor were obtained from the response of patients. Whereas, the daily wage rate of daily paid patients and companion were estimated based on the patients reported daily earnings. The indirect costs of unemployed patients, such as students and patients who were not working due to physical or mental disability, were not considered in the calculations.

- 196 All direct costs, indirect costs and productivity losses were initially collected in Ethiopian currency
- 197 (birr) and then converted to US \$ during the analysis. A currency exchange rate of 1US \$=27.471
- 198 Ethiopian Birr as of August 2018 was employed in the analysis.

#### 199 Data sources

The sources of information's for estimating the costs of hypertension illness were both patients and medical records. Direct cost of illness was estimated based on the information obtained through patient interview and record review. Information related to indirect costs such as costs of transportation and logging were gathered through patients and companion interviews (Table 1).

### 204 Data analysis

Paper based data were checked for completeness and consistency. Following this, data were
entered by using Epidata version 3.1 and exported to SPSS 20 for analysis.

The analysis was performed in such a way that, first, descriptive statistics was conducted to analyze information related to the characteristics of patients and to estimate the costs of hypertension illness. Following this, cost of illness data were checked for normality by using plots (Q-Q plots and histograms) and Kolmogorov-Smirnov test for normality (P>0.05). By doing so, the cost data were found to be right skewed and log transformation was performed to approximately conform the skewed data to normality.

Multivariate linear regression analysis was conducted to identify the predictors of the total cost ofhypertension illness among patients.

In the regression model, independent variables with a probability value (P-value < 0.05) have been entered and only statistically significant variables (P-value < 0.05) were included into the final model and interpreted.

### 218 Ethical Considerations

Research protocol was submitted to Jimma University Institute of health ethics review board and 219 220 ethical clearance was obtained (protocol number IHRPGD/453/2018, July 2018). Research ethical clearance and permission was also obtained from Oromia regional health bureau and Southwest 221 222 Shewa zone health department. The objective of the study was briefly explained to research participants followed by consent as assurance to their voluntary participation. The confidentiality 223 of patient's information was maintained throughout the data collection and analysis processes. 224 225 Codes were used instead of patient identifying information's and patient's data were kept in a locked cabinet and in a password secured computers. Except the research team members, no one 226 227 can access the patients data without due consent of individual patients.

## 228 **Results**

#### 229 Participation

Out of the total planned 354 patients, 349 were participated in the study making a response rate of98.6%.

### 232 Characteristics of patients

Table 2 presented the characteristics of patients in the study area. The mean age of patients was 52
years (SD 14). The youngest patient was 22 years and the oldest one was 88 years. A bit more than
half (52%) of patients were male. The majority of patients were married (80%), orthodox religion
followers (56%), have no education (44%), employed (78%) and from urban settings (60%) (Table
2). The average monthly income of patients and households were 115.4 US \$ (SD 70.1) and 136.8
US \$ (SD 105.9), respectively.

#### 239 Cost of hypertension illness

240 Cost by patients

241 Table 3 presented the direct and indirect cost of hypertension illness among patients on follow-up care by cost category. The estimated total direct cost of hypertension illness was 3032.3 US \$ .The 242 mean direct cost of hypertension illness was US \$ 8.8 (95% CI, 8.2-9.3). Most (60%) of the direct 243 costs of hypertension illness were attributed to medical costs (mean annual cost, US \$ 5.2; 95% 244 CI, 4.8-5.5). The direct medical costs comprised of cost for drugs, laboratory tests, registration and 245 246 cost for non-prescribed drugs. Slightly over two-thirds (69%) of total medical costs were 247 contributed by the cost of drugs alone (mean annual cost, US \$ 3.6; 95% CI, 3.4-3.8). While costs for laboratory tests and registration were accounted of 13% (mean annual cost, US \$ 1.2; 95% CI, 248 249 1.1-1.4) and 7% (mean annual cost, US \$ 0.4; 95% CI, 0.37-0.39) of the total medical costs, respectively (Table 3). 250

On average patients have visited hospitals once per month and half of patients have used bus as a
means of transportation to visit hospitals. The mean lost earning day of patients due to hypertension

illness was one working day. The total cost of lost earning was US \$ 1, 927.9 and on average each
patients paid US \$ 6.7 (95% CI, 6.3-7.0) (Table 3).

#### 255 Cost by companions

Table 4 presented the costs of hypertension illness paid by companions. Out of the total patients who have visited hospitals (349), the majority (87%; 95% CI, 83-90) had family or friend that accompany them. Half of the companions (52%; 95%, CI 46-57) have lost some portion of their income as they care patients. The mean direct cost of companion was US\$ 3.1 (95% CI, 2.7-3.6) and the mean forgone earning by the companion as the result of hypertension illness was US \$ 6.2 (95% CI, 5.9-6.5) (Table 4).

#### 262 Total cost of hypertension illness

Table 5 presented the total cost of hypertension illness. The total cost of hypertension illness was US \$ 7,773.5(mean monthly cost, US \$ 22.3; 95% CI, 21.3-23.3). Out of these, direct costs accounted of 51% or US \$ 3,973.8. The mean monthly and annual direct cost of hypertension illness per patient were US\$ 11.4 (95% CI, 10.6-12.1) and US \$ 136.6 (95% CI, 127.7-145.5), respectively (Table 5).

The mean monthly and annual indirect costs of hypertension illness per patient were US \$ 10.9 (95% CI, 10.4-11.4) and US \$ 130.7, respectively. Indirect cost was the time devoted by hypertension patients and companion in one month recall period. It included detail time spent by patients and companion. Indirect cost was expressed by the lost days of patients and companion during the follow-up visits or seeking treatments. A total of 833 days were used by patients and companion with median of 1.9 days in one month period. The time spent by patients and companion to visit hospital was 26,585 minute with median of 60 minutes (round trip) (Table 5).

### 275 Predictors of cost of hypertension illness

Table 6 presented the bivariate and multivariate linear regression analysis results. In the bivariate linear regression analysis variables such as gender, marital status, educational status, family size, residence, distance from hospital, presence of companion and stage of hypertension were associated with total cost of hypertension illness.

After adjusted for other independent variables, educational status, distance from hospital, presence of companion and stage of hypertension were statistically associated with the total cost of illness. Twenty three percent (23%) of the variability in the total cost of hypertension illness was explained by these variables (Table 6).

Patients with no education have a higher total cost of hypertension illness compared to patients with a primary educational level ( $\beta$ -coefficient=-0.07; 95% CI, (-0.124,-0.020).

The total cost of hypertension illness increased with the increase in distance to hospital. With a unit increase in distance to hospitals, the total cost of hypertension illness increased by about US \$ 0.003(95% CI, 0.002, 0.004) keeping the other variables constant.

Moreover, the total cost of hypertension illness was associated with the presence of companion and the stage of hypertension. The total cost of hypertension was higher among patients who have companion compared to those who didn't have ( $\beta$ -coefficient=0.096; 95% CI, 0.057, 0.135). Likewise, the total cost of hypertension illness was higher among patients in the hypertension stage of two compared to patients in the prehypertension stage ( $\beta$ -coefficient=0.070; 95% CI, 0.023, 0.118) (Table 6).

# 295 **Discussion**

- Cost of illnesses analysis is useful to understand the burden of a particular disease in a society(29-296 297 31). In this study we estimated the cost of hypertension illness among patients on follow-up care. 298 The estimated total cost of hypertension illness was 7775.5 USD and out of these direct cost 299 accounted of 51%. The average annual cost of hypertension illness among patients was US \$ 267.2. 300 Likewise, the annual mean direct and indirect costs per patients were US \$ 136.6 and US \$ 130.7, 301 respectively. In this study variables such as educational status, distance from hospital, the presence 302 of companion and stage of hypertension were the predictors of the total cost of hypertension illness in the study area. 303
- The cost of hypertension illness was lower that a study conducted in Kenya, where the mean annual direct and indirect cost to patient were US\$ 304.8 (95% CI, 235.7-374.0) and US\$ 171.7 (95% CI, 152.8-190.5), respectively (23). However, the cost of hypertension illness was higher than a study conducted in India (32) and Addis Ababa (26). This difference might be due to variation in settings, period and methods of cost estimation employed.
- A bit over half of the total cost of hypertension illness was contributed by direct medical and direct non-medical costs. Most of the direct costs were due to drugs followed by accommodation and transportation. In the study setting, direct medical cost accounted of 29% of the direct cost of hypertension illness. A comparable result was also reported in other settings in which much of the cost of hypertension illness was attributed to medicines(21–23,26,32,33). This might be related to the high cost of hypertension drugs and this implied a higher rates of catastrophic costs on hypertension patients.

316 Nonetheless, the indirect costs of hypertension illness were also equally important. These costs 317 included the time spent by patients and their companion, and expressed as lost work days. The majority of patients had companion and the mean forgone earning by the companion due to 318 319 hypertension illness was US\$ 6.2. The estimated average annual indirect cost of hypertensive 320 illness was US \$ 130.7 and this is lower than a report from Kenya(23). However, the indirect cost 321 of hypertensive illness was high in the study area and it accounted of 49% of the total cost of 322 illness. Indirect cost of hypertensive illness was attributed to the travel time to the hospital and 323 absent from work. This indicates the need for expanding hypertension management centers and 324 enhancing the control of hypertension in a community. In Ethiopia the coverage of noncommunicable diseases management services was low and increasing steadily (34). 325

The cost of hypertension illness was determined by educational status, distance from the hospital, 326 327 presence of companion and the stage of hypertension illness. The cost of hypertension illness was higher in no educated patients than the primary level education patients. This might be due to the 328 reason that in the study setting most of the patients with a no educational status were at stage two 329 of hypertension and the complications related to hypertension may let them to cost more. The total 330 331 cost of hypertension was also associated with the presence of companion and distance to hospital. 332 With a unit increase in distance to hospital, the cost of hypertension illness increased by about 333 0.003 US \$. This is due to the fact that the companion consumption (food and transport) and the 334 transportation cost of patients to visit hospitals may increases the total cost of hypertension illness. Likewise, patients who were in stage two of hypertension have a higher cost of illness than those 335 in the prehypertension stage. This implies that the complications of hypertension is a significant 336 337 contributor to increase in the cost of illness and this warrants the early diagnosis and management of hypertension. Our findings are comparable to other reports elsewhere(21,32). 338

Though our study have a many strengths, it has also some limitations. The cost of illness analysis was limited to patient's perspective and doesn't addressed other costs of the health system (such as costs related to the provider, family and society at large). Moreover, the intangible cost (costs of pain, suffering, stigma and discrimination) associated with hypertensive illness were not also addressed in our study.

# 344 Conclusion

Overall, this study have revealed that the total cost of hypertension illness was high in the study area. The mean total cost of hypertension illness was high compared to the mean monthly income of patients and households, letting patients to catastrophic costs. Unless urgent measures were taken, the increased prevalence of hypertension combined to the high cost of hypertension management in Ethiopia may bare individuals to financial hardships. Thus, the government should take attention in preventing further catastrophic costs resulted from the complications and mortality of hypertension.

## 352 Acknowledgments

353 Our sincere gratitude should goes to the participants of the study and the administrative offices for 354 their cooperation throughout the data collection process.

# **355** Author contributions

All authors contributed toward conceiving idea, study design and data analysis. DWD drafted themanuscript and AB and TB revised the paper. All authors also gave final approval of the paper.

# 358 **Disclosure**

359 All authors declared no conflict of interest.

## 360 **References**

- 1. American College of Cardiology. Guideline for the Prevention, Detection, Evaluation,
- and Management of High Blood Pressure in Adults [Internet]. 2017. Report No.: 23976.
- 363 Available from: https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-
- 364 etc/Guidelines/2017/Guidelines\_Made\_Simple\_2017\_HBP.pdf
- 2. World Health Organization. Hypertension: Key facts [Internet]. 2019. Available from:

366 https://www.who.int/news-room/fact-sheets/detail/hypertension

- 367 3. World Health Organization. A global brief on hypertension: Silent killer, global public
- health crisis. World Health Day 2013 [Internet]. 2013. Available from: https://ish-

369 world.com/downloads/pdf/global\_brief\_hypertension.pdf

- 4. Campbell N, Lackland D, Niebylski M. High Blood Pressure : Why Prevention and
- 371 Control are Urgent and Important . A 2014 Fact Sheet from the World Hypertension
- 372League and the International Society of Hypertension Increased blood pressure is the

leading risk factor for death and for disability. Int Soc Hypertens. 2014;(1):5.

- The P, On P, Killer THES. HYPERTENSION :PUTTING THE PRESSURE ON THE
  SILENT KILLER. IFPMA; 2016. 3–19 p.
- Lloyd-Jones DM, Levy D. Epidemiology of Hypertension. Hypertens A Companion to
   Braunwald's Hear Dis. 2013;61(February):1–22.
- 378 7. Salem H, Hasan DM, Eameash A, El-Mageed HA, Hasan S, Ali R. Worldwide Prevalence

379		of Hypertension: a Pooled Meta-Analysis of 1670 Studies in 71 Countries With 29.5
380		Million Participants. J Am Coll Cardiol [Internet]. 2018;71(11):A1819. Available from:
381		http://dx.doi.org/10.1016/S0735-1097(18)32360-X
382	8.	Misganaw Dr. A, Mariam DH, Ali A, Araya T. Epidemiology of major non-
383		communicable diseases in Ethiopia: A systematic review. J Heal Popul Nutr [Internet].
384		2014;32(1):1-13. Available from: http://www.bioline.org.br/pdf?hn14001
385	9.	Roba HS, Beyene AS, Mengesha MM, Ayele BH. Prevalence of Hypertension and
386		Associated Factors in Dire Dawa City, Eastern Ethiopia: A Community-Based Cross-
387		Sectional Study. Int J Hypertens. 2019;
388	10.	Belachew A, Tewabe T, Miskir Y, Melese E, Wubet E, Alemu S, et al. Prevalence and
389		associated factors of hypertension among adult patients in Felege-Hiwot Comprehensive
390		Referral Hospitals, northwest, Ethiopia: A cross-sectional study. BMC Res Notes
391		[Internet]. 2018;11(1):876. Available from: https://doi.org/10.1186/s13104-018-3986-1
392	11.	Abebe S, Yallew WW. Prevalence of hypertension among adult outpatient clients in
393		hospitals and its associated factors In Addis Ababa , Ethiopia : a hospital based cross -
394		sectional study. BMC Res Notes [Internet]. 2019;12:87. Available from:
395		https://doi.org/10.1186/s13104-019-4127-1
396	12.	Abebe SM, Berhane Y, Worku A, Getachew A. Prevalence and associated factors of
397		hypertension: A crossectional community based study in Northwest Ethiopia. PLoS One.
398		2015;10(4):1–11.
200	10	

399 13. Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: A systematic meta400 analysis. Public Health Rev [Internet]. 2015;36(1):14. Available from:

#### 401 http://dx.doi.org/10.1186/s40985-015-0014-z

422

- 402 14. World Health Organization. Age Adjusted Death Rate Estimate. The Health Profile of 403 Ethiopia. 2017. Accessed at: https://www.worldlifeexpectancy.com/country-health-404 profile/ethiopia. Misganaw A, Haregu TN, Deribe K, Tessema GA, Deribew A. National mortality burden 15. 405 406 due to communicable , non-communicable , and other diseases in Ethiopia , 1990 - 2015: findings from the Global Burden of Disease Study 2015. Popul Health Metr [Internet]. 407 408 2017;15:29. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521057/ 409 16. Federal Democratic Republic of Ethiopia National Plan Commission. The 2017 Voluntary 410 National Reviews on SDGs of Ethiopia: Government Commitments, National Ownership 411 and PerformanceTrends. Addis Ababa [Internet]. 2017. Available from: https://sustainabledevelopment.un.org/content/documents/16437Ethiopia.pdf 412 FMoH of Ethiopia. Health Sector Transformation Plan (HSTP) 2015/16-2019/20 413 17. [Internet]. 2015. Available from: https://www.globalfinancingfacility.org/ethiopia-health-414 sector-transformation-plan-201516-201920 415 416 18. FDRE MOH. National Strategic Action Plan (NSAP) for Prevanetion and Control of Noncommunicable diseases in Ethiopia. 2014-2016 [Internet]. 2016. Available from: 417 418 https://www.iccp-portal.org/system/files/plans/ETH\_B3\_National Strategic Action Plan 419 %28NSAP%29 for Prevention and Control of Non-Communicable Diseases - Final.pdf 19. GAVI CSO Project fact sheet. What are the Health System Building Blocks? [Internet]. 420 421 2013. Available from:
  - 20

https://hssfactsheets.weebly.com/uploads/4/8/1/1/48110245/gavi\_cso\_fact\_sheet\_no\_5\_bu

### 423 ilding\_blocks.pdf

424	20.	Christopher Murray and Julio Frenk. A WHO Framework for Health System Performance
425		Assessment. Evidence and Information for policy. World Health Organization [Internet].
426		Available from:
427		https://www.researchgate.net/publication/12402824_A_WHO_Framework_for_Health_Sy
428		stem_Performance_Assessment
429	21.	Nguyen T, Bach T, Nguyen Y, Nguyen TT, Hac VV, Le HH. Direct costs of hypertensive
430		patients admitted to hospital in Vietnam – a bottom-up micro-costing analysis. BMC
431		Health Serv Res. 2014;14:514.
432	22.	Alefan Q, Ibrahim MIM, Razak TA, Ayub A. COST OF TREATING HYPERTENSION
433		IN MALAYSIA. Asian J Pharm Clin Res. 2009;2(1):1–5.
434	23.	Njoroge M, Nguhiu P, Oyando R, Kirui F, Mbui J, Sigilai A, et al. Patient costs of
435		hypertension care in public health care facilities in Kenya. Int J Heal Plann Mgmt.
436		2019;34:e1166–e1178.
437	24.	Wagner AK, Valera M, Graves AJ, Laviña S, Ross-degnan D. Costs of hospital care for
438		hypertension in an insured population without an outpatient medicines benefit : an
439		observational study in the Philippines. BMC Health Serv Res. 2008;8:161.
440	25.	Baker-goering MM, Roy K, Howard DH. Relationship Between Adherence to
441		Antihypertensive Medication Regimen and Out- of-Pocket Costs Among People Aged 35
442		to 64 With Employer-Sponsored Health Insurance. PUBLIC Heal Res Pract POLICY.
443		2019;16:180381.

- 444 26. Bedane SN. Out of Pocket Expenditures among Hypertensive Patients and their
- Households who Visit Public Hospitals in Addis Ababa, Ethiopia, 2016. Heal Econ
- 446 Outcome Res Open Access. 2018;4(1):1-7.
- 447 27. Dhar M, Binu V, Mayya S. Some basic aspects of statistical methods and sample size
- determination in health science research. AYU (An Int Q J Res Ayurveda) [Internet].
- 449 2014;35(2):119–23. Available from:
- 450 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279315/
- 451 28. World Health Organization Global TB Programme. Protocol for survey to determine
- direct and indirect costs due to TB and to estimate proportion of TB-affected households
- 453 experiencing catastrophic costs due to TB. November [Internet]. 2015. Available from:
- 454 http://www.who.int/tb/advisory\_bodies/impact\_measurement\_taskforce/meetings/tf6\_bac
- 455 kground\_5a\_patient\_cost\_surveys\_protocol.pdf?ua=1
- 456 29. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol [Internet].
- 457 2014;20:327–37. Available from:
- 458 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278062/
- 459 30. Segel JE. Cost-of-Illness Studies A Primer.RTI International. RTI-UNC Center of
- 460 Excellence in Health Promotion Economics [Internet]. 2006. p. 1–39. Available from:
- 461 https://pdfs.semanticscholar.org/3bbf/0a03079715556ad816a25ae9bf232b45f2e6.pdf
- 462 31. Byford S, Torgerson DJ, Raftery J. Cost of illness studies. BmJ [Internet]. 2000;320:1335.
  463 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1127320/
- 464 32. Sitanshu Sekhar Kar, Vinoth Kumar Kalidoss, Uma Vasudevan SG. Cost of care for
- 465 hypertension in a selected health center of urban Puducherry : An exploratory cost-of-

466		illness study. Int J Non-communicable diseses [Internet]. 2018;3(3):98–103. Available
467		from: http://www.ijncd.org/article.asp?issn=2468-
468		8827;year=2018;volume=3;issue=3;spage=98;epage=103;aulast=Kar
469	33.	Donglan Zhang, Guijing Wang, Ping Zhang, Jing Fang, and Carma Ayala R. Medical
470		Expenditures Associated With Hypertension in the U.S., 2000–2013. Am J Prev Med.
471		2017;53(6):S164–S171.
472	34.	Ethiopian Public Health Institute. Services Availability and Readiness Assessment (
473		SARA ). 2018.
474		
475		
476		
477		
478		
479		
480		
481		
482		
483		

484 Table 1: Cost item, data source and data type for cost of hypertension illness estimation among

485 patients in South West Shewa Zone hospitals, Oromia Regional State, Ethiopia. August 2018

Cost category	Data	Method of data	Data type
	source	collection	
			Cost of registration, drugs,
Direct Medical	Patient/	Patient	laboratory, Admin cost ,if any
Cost	health	interview/record	investigations
	facility	review	
Direct non-	Patient	Patient interview	Cost of transport for
Medical Costs			patients/Escort, lodging
			accommodation
	Patient	Patient interview	Income loss by patients and
Indirect Medical			their families/relatives
Cost			

- 495 Table 2. Characteristics of hypertensive patients at hospitals of Southwest Shewa zone, Oromia
- 496 regional state, Ethiopia. August 2018

Variables	Observations	Mean/proportion (95% CI
	(n=349)	
Age (mean± SD)	51.2 (±13.9)	51.2 (50-53)
Gender		
Male	181	52% (47-57%)
Female	168	48% (43-53%)
Total		
Marital status		
Married	281	80% (76-84%)
Never married/single	27	8% (5-11%)
Widowed/ Divorced	41	12% (9-16%)
Religion		
Orthodox	202	58% (53-63%)
Muslim	78	22% (18-27%)
Protestant	69	20% (16-24%)
Highest education level		
No education	154	44% (39-49%)
Primary	57	16% (13-21%)
Secondary	68	20% (16-24%)
Higher	70	20% (16-25%)
Employment status		

Formal employment	144	41% (36-47%)
Informal/unemployed	205	59% (54-64%)
Family size		
1-3	49	14% (11-18%)
4-6	203	58% (53-63%)
>6	97	28% (23-33%)
lesidence		
Urban	210	60% (55-65%)
Rural	139	40% (35-45%)
verage distance from hospital in (km)		
<10	169	48% (43-54%)
11-20	57	16% (13-21%)
21-30	42	12% (9-16%)
31-40	36	11% (7-14%)
41-50	20	6% (4-9%)
50+	25	7% (5-10%)
lness duration		
1-5 у	242	69% (64-74%)
>5 y	107	31% (26-36%)
tage of hypertension		
Prehypertension	113	32% (28-37%)
Stage I	161	46% (41-51%)
Stage II	75	22% (17-26%)

#### 497 Table 3: Patient direct and indirect costs of hypertension illness at hospitals of Southwest Shewa

#### 498 zone, Oromia region, Ethiopia. August 2018 (US \$)

Cost item	Observations	Sum	Mean ± SD (Median)	95% CI for mean
Total Direct Cost	349	3,032.252	8.8±4.9(7.6)	(8.2-9.3)
Direct medical cost	349	1,804.230	5.2±3.3(4.7)	(4.8-5.5)
Cost of prescribed drugs	349	1,247.752	3.6±1.9(3.3)	(3.4-3.8)
Cost of different laboratory tests	186	231.371	1.2±0.9(0.9)	(1.1-1.4)
Cost registrations	349	133.413	0.38±0.1(0.4)	(0.37-0.39)
Cost of non-prescribed drugs	52	191.693	3.7±4.4(2.6)	(2.5-4.9)
Direct non-medical cost	339	1,228.022	3.6±3.2(2.9)	(3.3-3.9)
Cost of food during visit	278	505.078	1.8±1.5(1.5)	(1.6-1.9)
Cost of transport	302	369.335	1.2±1.2(0.7)	(1.1-1.4)
Cost of sport (gym) per	87	353.609	4.1±4.2(3.6)	(2.8-4.5)
month				
Income lost by patients	290	1,927.89	6.7±3.4	(6.3-7.0)
Number of outpatient visit(in	349	396	1.0±1.0	(0.9-1.1)
number)				
Days absent from work	349	459	1.3±1.3	(1.2-1.5)
Travel time to the hospital	349	14,145	40.5±34.5	(36.9-44.1)
(in minute)				
Waiting time in the hospital (in minutes)	349	10,715	30.7±14.7	(29.2-32.2)

499 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

#### **Table 4:** Companion direct and indirect costs of hypertension illness at hospitals of South West

502 Shewa Zone, Oromia Regional State, Ethiopia. August 2018 (US \$)

Cost category	Observations	Sum	Mean $\pm$ SD	95% CI for
			(Median)	mean
Direct cost by companions	302	941.5	3.1±4(2.2)	(2.7-3.6)
Payment for Food	247	493.2	1.9±3.8(1.1)	(1.5-2.5)
Transportation Fee	302	369.3	1.2±1.2(0.7)	(1.1-1.4)
Cost for Other expenses	33	78.9	2.4±1.9(2.4)	(1.7-3.1)
Indirect cost by companions	302	1,871.8	6.2±2.3(5.5)	(5.9-6.5)
(income lost by companions)				
Travel time by caregivers in	302	12,440	41.2±34.9(30.0)	(37.3-45.1)
minute/month				
Days absent from work to	302	376	1.0±1.0(1.0)	(0.9-1.1)
accompany/month				

<sup>503</sup> Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

#### **Table 5:** Total cost of hypertension illness at hospitals of Southwest shewa zone, Oromia regional

509 state, Ethiopia. August 2018 (US \$)

Cost category	Observations	Sum	Mean ± SD	95% CI for
			(Median)	mean
Total cost of hypertension	349	7,773.47	22.3±9.4(20.8)	(21.3-23.3)
Total direct cost of patients	349	3,973.75	11.4±7.1(10.0)	(10.6-12.1)
and companions				
Direct medical costs	349	1,804.23	5.2±3.4(4.7)	(4.8-5.5)
Cost of prescribed drug	349	1,247.752	3.6±1.9(3.3)	(3.4-3.8)
Cost of laboratory test	186	231.371	1.2±0.9(0.9)	(1.1-1.4)
Cost of registration card	349	133.413	0.4±0.1(0.4)	(0.37-0.39)
Cost non-prescribed drug	52	191.693	3.7±4.4(2.6)	(2.5-4.9)
Direct non-medical costs	339	2,169.52	6.5±5.9(5.2)	(5.9-7.1)
Cost of Food	299	998.25	3.3±4.2(2.2)	(2.9-3.8)
Cost of transport	302	738.67	2.5±2.3(1.6)	(2.2-2.7)
Cost for sport(gym)	87	353.61	4.2±4.2(3.6)	(3.3-5.0)
Other costs	33	78.99	2.4±1.9(2.4)	(1.7-3.1)
Indirect costs of patients and				
companions				
Income lost by patients &	349	3,799.72	10.9±5.0(10.9)	(10.4-11.4)
companions				
Travel time to the hospital in	349	26,585.00	76.3±67.9(60.0)	(69.1-83.4)
minute/month				
Absent from works in	349	833.00	2.0±1.0(1.9)	(1.9-2.1)
days/month				

510 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

- 512 Table 6: Predictors of the total cost of hypertension illness among patients at hospitals of
- 513 Southwest Shewa zone, Oromia regional state, Ethiopia. August 2018(US \$)

Variables	Observations	Unadjusted β	Adjusted β	
		coefficient (95% CI)	coefficient (95% CI)	
Age in years (Mean ± SD)	51.2 (±13.9)	0.0001(-0.001,0.002)		
Gender				
Male	181			
Female	168	-0.070(-0.113, -0.027)*	-0.037(-0.077,-0.004)	
Educational status				
No education	154			
Primary	57	-0.068(-0.126,-0.009)*	-0.072(-0.124,-0.020)*	
Secondary	68	0.007(-0.047,0.062)		
Tertiary	70	0.002(-0.052,0.056)		
Marital status				
Married	281			
Single	27	0.030(-0.051,0.112)		
Divorced/widowed	41	-0.091(-0.157,-0.024)*	-0.057(-0.121,0.006)	
Family size				
1-3	49			
4-6	203	0.106(0.044,0.169)*	0.029(-0.010,0.068)	
>6	97	0.122(0.050,0.195)		
Residence				
Urban	210			
Rural	139	0.062(0.018,0.106)*	0.020(-0.021,0.060)	
Distance from hospital (Km)	21.6±23.7	0.003(0.002,0.004)*	0.003(0.002,0.004)*	
Presence of companion				
Yes	153	0.106(0.064-0.149)*	0.096(0.057,0.135)*	
No	196			
Stage of hypertension				
Pre-hypertension	113			

Stage one	161	-0.007(-0.051,0.036)	
Stage two	75	0.074(0.021,0.126)*	0.070(0.023,0.118)*
Duration of hypertension			
illness			
1-5 year	242		
>5 year	107	-0.027(-0.074,0.020)	
Presence of comorbidity			
Yes	227		
No	122	0.012(-0.034,0.057)	

### Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval;

515 \*P-value<0.05